Report Overview

The Global Colorectal cancer drugs market size stood at USD 14.3 billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

Colorectal cancer is cancer that starts in the colon or rectum. The colon and the rectum are parts of the large intestine, which is the lower part of the bodys digestive system. The colon absorbs water and nutrients from the food and stores waste matter (stool). Stool moves from the colon into the rectum before it leaves the body. Colorectal cancer often begins as a growth called a polyp, which may form on the inner wall of the colon or rectum. Some polyps become cancer over time. Finding and removing polyps can prevent colorectal cancer. During digestion, food moves through the stomach and small intestine into the colon. Most colorectal cancers are adenocarcinomas (cancers that begin in cells that make and release mucus and other fluids). Some of the commonly seen symptoms of colorectal cancer are blood in the weight loss, fatigue, stool, and irregular bowel movements. Colorectal cancer is a result of uncontrolled cell growth that occurs in the appendix, colon, and the rectum region.



Market Drivers

The main drivers of growth include the anticipated approval and launch of 9 pipeline therapies, in addition to label expansions of currently marketed therapies across the 8MM during the forecast period.

The main barriers to growth in the 8MM include the patent expiry of major brands and the high price of premium priced therapeutics entering the market.